Abstract
Basic fibroblast growth factor (bFGF or FGF-2) is produced by nearly all melanomas in vitro and in vivo but not by normal melanocytes, which require exogenous bFGF for growth. In this study, we transduced normal human melanocytes to overexpress two forms of bFGF: (bFGF-Long and bFGF-Short) using replication-deficient adenovirus 5 vectors. bFGF-Long induced the 17.8, 22.5, 23.1 and 24.2 kDa forms of bFGF, whereas bFGF-Short induced only the 17.8 kDa mature form. Growth of cultured melanocytes transduced with either vector was similar to that of nevus and melanoma cells and was independent of exogenous bFGF and of insulin/insulin-like growth factor 1, and cyclic AMP enhancers, requiring only phorbol ester as an exogenous mitogen. Like primary melanoma cells, transduced normal melanocytes grew anchorage independently in soft agar. When injected into the dermis of human skin grafted to mice, bFGF-transduced melanocytes proliferated for at least 20 days, whereas cells from control cultures showed poor survival and no proliferation. These results demonstrate that bFGF upregulation is a critical component in melanoma progression.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Abdel-Malek Z, Swope VB, Pallas J, Krug K and Nordlund JJ. . 1992 J. Cell Physiol. 150: 416–425.
Ahmed NU, Ueda M, Ito A, Ohashi A, Funasaka Y and Ichihashi M. . 1997 Mel. Res. 7: 299–305.
al-Alousi S, Barnhill R, Blessing K and Barksdale S. . 1996a J. Cut. Pathol. 23: 506–510.
al-Alousi S, Carlson JA, Blessing K, Cook M, Karaoli T and Barnhill RL. . 1996b J. Cut. Pathol. 23: 118–125.
Albino AP, Davis BM and Nanus DM. . 1991 Cancer Res. 51: 4815–4820.
Amalric F, Bouche G, Bonnet H, Brethenou P, Roman AM, Truchet I and Quarto N. . 1994 Biochem. Pharmacol. 47: 111–115.
Baldin V, Roman AM, Bosc-Bierne I, Amalric F and Bouche G. . 1990 EMBO J. 9: 1511–1517.
Becker D, Lee PL, Rodeck U and Herlyn M. . 1992 Oncogene 7: 2303–2313.
Becker D, Meier CB and Herlyn M. . 1989 EMBO J. 8: 3685–3691.
Bouche G, Baldin V, Belenguer P, Prats H and Amalric F. . 1994 Cell. Mol. Biol. Res. 40: 547–554.
Care A, Silvani A, Meccia E, Mattia G, Stoppacciaro A, Parmiani G, Peschle C and Colombo MP. . 1996 Mol. Cell. Biol. 16: 4842–4851.
Cohen-Jonathan E, Toulas C, Monteil S, Couderc B, Maret A, Bard JJ, Prats H, Daly-Schveitzer N and Favre G. . 1997 Cancer Res. 57: 1364–1370.
Coleman AB and Lugo TG. . 1998 J. Invest. Dermatol. 110: 793–799.
Czubayko F, Liaudet-Coopman ED, Aigner A, Tuveson AT, Berchem GJ and Wellstein A. . 1997 Nature Med. 3: 1137–1140.
Davol P, Beitz JG and Frackelton Jr AR. . 1995 J. Invest. Dermatol. 104: 916–921.
De Luca M, Siegrist W, Bondanza S, Mathor M, Cancedda R and Eberle AN. . 1993 J. Cell Sci. 105: 1079–1084.
deOliveira AR, Castrucci AM and Visconti MA. . 1996 Brazilian J. Med. Biol. Res. 29: 1743–1749.
Dotto GP, Moellmann G, Ghosh S, Edwards M and Halaban R. . 1989 J. Cell Biol. 109: 3115–3128.
Florkiewicz RZ, Anchin J and Baird A. . 1998 J. Biol. Chem. 273: 544–551.
Florkiewicz RZ and Sommer A. . 1989 Proc. Natl. Acad. Sci. USA 86: 3978–3981.
Gualandris A, Urbinati C, Rusnati M, Ziche M and Presta M. . 1994 J. Cell Physiol. 161: 149–159.
Halaban R, Kwon BS, Ghosh S, Delli Bovi P and Baird A. . 1988 Oncogene Res. 3: 177–186.
Herlyn M, Mancianti ML, Jambrosic J, Bolen JB and Koprowski H. . 1988 Exp. Cell Res. 179: 322–331.
Herlyn M and Shih IM. . 1994 Pig. Cell Res. 7: 81–88.
Herlyn M, Thurin J, Balaban G, Bennicelli JL, Herlyn D, Elder DE, Bondi E, Guerry D, Nowell P, Clark WH et al. 1994 Cancer Res. 45: 5670–5676.
Horikawa T, Norris DA, Zekman T and Morelli JG. . 1996 Pig. Cell Res. 9: 58–62.
Hsu MY, Shih DT, Meier FE, Van Belle P, Hsu JY, Elder DE, Buck CA and Herlyn M. . 1998 Am. J. Path. 153: 1435–1442.
Hsu MY, Elder DE and Herlyn M. . 1999 Melanoma: The Wistar (WM) melanoma cell lines, In: Masters JRW and Palsson B (eds). Human cell culture. Kluwer Acad. Publications: London. pp. 259–274.
Juhasz I, Albelda SM, Elder DE, Murphy GF, Adachi K, Herlyn D, Valyi-Nagy IT and Herlyn M. . 1993 Am. J. Path. 143: 528–537.
Kozarsky KF and Wilson JM. . 1993 Curr. Opin. Genet. Devel. 3: 499–503.
Mancianti ML, Gyorfi T, Shih IM, Valyi-Nagy I, Levengood G, Menssen HD, Halpern AC, Elder DE and Herlyn M. . 1993 J. Invest. Dermatol. 100: 281S–287S.
Nakazawa K, Nakazawa H, Sahuc F, Damour O and Collombel C. . 1996 Pig. Cell Res. 9: 28–34.
Nelson JE and Kay MA. . 1997 J. Virol. 71: 8902–8907.
Prats AC, Vagner S, Prats H and Amalric F. . 1992 Mol. Cell. Biol. 12: 4796–4805.
Quarto N, Talarico D, Florkiewicz R and Rifkin DB. . 1991 Cell Reg. 2: 699–708.
Quarto N, Talarico D, Sommer A, Florkiewicz R, Basilico C and Rifkin DB. . 1989 Onc. Res. 5: 101–110.
Reed JA, McNutt NS and Albino AP. . 1994 Am. J. Path. 144: 329–336.
Rodeck U, Herlyn M, Menssen HD, Furlanetto RW and Koprowsk H. . 1987 Int. J. Cancer 40: 687–690.
Satyamoorthy K, DeJesus E, Linnenbach AJ, Kraj B, Kornreich DL, Rendle S, Elder DE and Herlyn M. . 1997 Mel. Res. 7: S35–S42.
Satyamoorthy K, Nesbit M, Hsu M-Y and Herlyn M. . (1996). In: Maio M. (ed Immunology of Human Melanoma: Tumor-Host Interaction and Immunotherapy. IOS Press. pp. 71–77.
Scott G, Stoler M, Sarkar S and Halaban R. . 1991 J. Invest. Dermatol. 96: 318–322.
Seno M, Masago A, Nishimura A, Tada H, Kosaka M, Sasada R, Igarashi K, Seno S and Yamada H. . 1998 Cytokine 10: 290–294.
Ueda M, Funasaka Y, Ichihashi M and Mishima Y. . 1994 Br. J. Dermatol. 130: 320–324.
Valyi-Nagy IT, Hirka G, Jensen PJ, Shih IM, Juhasz I and Herlyn M. . 1993 Lab. Invest. 69: 152–159.
Wang Y and Becker D. . 1997 Nature Med. 3: 887–893.
Weitzman MD, Wilson JM and Eck SL. . (1995). In: Sobol RE and Scanlon KJ (eds Cancer Therapeutics. Appleton and Lange.
Yan HC, Juhasz I, Pilewski J, Murphy GF, Herlyn M and Albelda SM. . 1993 J. Clin. Invest. 91: 986–996.
Yayon A, Ma YS, Safran M, Klagsbrun M and Halaban R. . 1997 Oncogene 14: 2999–3009.
Acknowledgements
This work was supported in part by NIH grants CA47159, CA25874, CA76674, CA74294, DK50306, CA10815, EY10820, EY12156, and NASA grant NAG 9-832.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nesbit, M., Nesbit, H., Bennett, J. et al. Basic fibroblast growth factor induces a transformed phenotype in normal human melanocytes. Oncogene 18, 6469–6476 (1999). https://doi.org/10.1038/sj.onc.1203066
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1203066
Keywords
This article is cited by
-
FGF2 Stimulates the Growth and Improves the Melanocytic Commitment of Trunk Neural Crest Cells
Cellular and Molecular Neurobiology (2020)
-
Sensitivity of Melanoma Cells to EGFR and FGFR Activation but Not Inhibition is Influenced by Oncogenic BRAF and NRAS Mutations
Pathology & Oncology Research (2015)
-
A novel FGF2 antagonist peptide P8 with potent antiproliferation activity
Tumor Biology (2014)
-
Increased angiogenesis and FGFR protein expression indicate a favourable prognosis in bladder cancer
Virchows Archiv (2014)
-
A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours
British Journal of Cancer (2012)